Immunic to Host Virtual R&D Day on Multiple Sclerosis

Immunic, a biotechnology company, will hold a virtual R&D day on September 9, 2026, focusing on relapsing multiple sclerosis (MS). The event will provide insights into vidofludimus calcium, an investigational oral therapy aiming to address neurodegenerative and inflammatory aspects of MS. Erik Lundgren, CEO of Immunic, alongside other executives, will lead the event featuring expert perspectives from Drs. Amit Bar-Or and Stephen Krieger.

The R&D day comes ahead of the anticipated Phase 3 ENSURE trials data for vidofludimus calcium, expected later this year. The therapy combines nuclear receptor-related 1 activation with selective DHODH inhibition, potentially offering a novel treatment approach for MS. The webinar will be accessible via Zoom, welcoming participants interested in the advancements of MS treatments.